Using data from health plan claims for the anti-cancer drug imatinib filed between 2002 to 2011, Stacie B. Dusetzina, PhD, research professor at the UNC School of Medicine and Gillings School of Global Public Health and member of the UNC Lineberger Comprehensive Cancer Center, found that patients with higher co-payments were 70 percent more likely to stop taking their cancer treatment and 42 percent more likely to skip doses.
The study, published by the Journal of Clinical Oncology is one of the first to examine the effect of high out-of-pocket drug costs for targeted cancer therapies on patients.
Dusetzina, along with colleagues from UNC, Harvard and the Dana-Farber Cancer Institute, used health plan claims from privately-insured adult patients (ages 18 to 64) from 2002 and 2011 to examine the relationship between out-of-pocket costs for imatinib, marketed under the trade name Gleevec in the United States, and patient adherence. The data showed that insurance co-payments for imatinib ranged from nothing to $4,792 for a 30-day supply of the medicine, with the costs increasing over the study years.
Imatinib is one of the major success stories of modern pharmaceutical development. Before the development of the drug, a patient with the white blood cell cancer chronic myeloid leukemia (CML) had a grim prognosis, with only 30 percent surviving more than five years after diagnosis.
With the advent of imatinib, the five-year survival rate rises to 89 percent so long as patients adhere to the prescribed treatment plan. Evidence suggests that patients missing even 15 percent of prescribed doses can relapse, as the cancer develops resistance to the drug.
"Imatinib is an expensive drug, but it is a great example of a drug where there is not a lot of confusion about which patients will benefit. Most patients with CML will benefit. However, individuals need to take it almost perfectly, and not taking it can have severe medical consequences," said Dusetzina. "So maximizing adherence is crucial."
The data used in the study only included patients on employer-based plans. Most individuals had low out-of-pocket costs - the most common cost was $30 for a 30 day supply, but copayments and co-insurance amounts required of patients varied substantially.
"We studied people who are part of large employer groups, so their insurance is probably more generous than someone who is buying insurance on a private market that does not have a lot of negotiating power," said Dusetzina.
Monthly co-payments for imatinib from patients in data used by the study averaged $55 in 2002 and $145 in 2012, with 6.4 percent paying more than $500 a month. The combined monthly costs of the drug to the insurance company and patient increased from 2,798 to $4,892 over the same period. The data did not include patients who were not able to afford to pay to begin taking the drug, which leads Dusetzina to believe that the study underestimates the effects of drug costs on adherence.
"If you went to the pharmacy to obtain your prescription and they said it was $5,000 and you walked away because you couldn't afford to pay, you're not in the data; we could only study individuals who filled at least one prescription," said Dusetzina.
Dusetzina said that the data has implications beyond imatinib. The cost of many new pharmaceuticals for rare conditions can cost insurers and patients more than $100,000 year.
"Our results are particularly relevant for specialty pharmaceutical products, those that cost over $10,000 a month, however, the lessons learned likely relate to any pharmaceutical product that has high out of pocket costs," said Dusetzina. "It is important that we identify strategies to make effective but expensive medications more affordable to patients."
William Davis | EurekAlert!
New study: How does Europe become a leading player for software and IT services?
03.04.2017 | Fraunhofer-Institut für System- und Innovationsforschung (ISI)
Reusable carbon nanotubes could be the water filter of the future, says RIT study
30.03.2017 | Rochester Institute of Technology
More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.
Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...
Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.
"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...
The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.
Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...
The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...
Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.
Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...
20.04.2017 | Event News
18.04.2017 | Event News
03.04.2017 | Event News
24.04.2017 | Physics and Astronomy
24.04.2017 | Materials Sciences
24.04.2017 | Life Sciences